Trial of DFP-14927 in Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Delta-Fly Pharma, Inc.
Study ID
NCT03943004
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Cancer
  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DFP-14927 — DRUG
    DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.

Study Details

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

Key Dates

Start date
Sep 30, 2019
Status verified
Feb 2025
Primary completion
Mar 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DFP-14927
    DFP-14927: weekly IV infusion, 28 day treatment cycle

Primary Outcome Measure

Determine the maximum tolerated dose (MTD) [ Time Frame: From first dose (Day 1) up to 30 days after last dose ]

Locations (2)

FacilityCityStateZIPSite coordinators
UCLA Department of Medicine- Hematology/OncologyLos AngelesCalifornia90095
Lisa Yonemoto
[email protected]
310-582-4069
Zev Wainberg, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030
Jackie Smith, R.N.
[email protected]
713-745-3917
Jaffer Ajani, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
UCLA Department of Medicine- Hematology/Oncology· Los Angeles, CAMD Anderson Cancer Center· Houston, TX

Related Studies